Loading...
You are viewing a DELETED record.
This record information is displayed for reference purpose only and should be not used.
This document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Rhodococcus equi Vaccine
EN
Rhodococcus equi RG2837, R. equi ΔipdABΔipdAB2
No
-
Person:IntervetWim de Körverstraat 35Boxmeer,
5831 AN, Netherlands (Kingdom of the)Phone: + 31 48 558 7600,Fax:Website: http://www.intervet.com, http://www.intervet.com,Related OrganizationIntervet International B.V. ()Academic or research instituteWim de Körverstraat 35Boxmeer,
5831 AN, Netherlands (Kingdom of the)Phone: + 31 48 558 7600,Fax:Website: http://www.intervet.com, http://www.intervet.com,
Rhodococcus equi RG2837 is a double-deletion mutant of the R. equi wild-type RE1. The original strain possesses the virulence plasmid VapA and triggers the typical clinical signs of respiratory diseases (pneumonia) in foals after infection. Although the LMO R. equi RG2837 also has the VapA plasmid, four introduced deletions in the bacterial chromosome prevent survival and proliferation of R. equi RG2837 in macrophages. Since this is a requirement for manifestation of an infection the deletion mutant is suitable to be used as a live-attenuated vaccine.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-107871-2 Organism Rhodococcus equi (RHOE1)Bacteria
EN
pSelAct-ipd1 and pSelAct-ΔipdAB2
EN
- Electroporation
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-107872-1 CoA-transferase alpha subunit gene | Rhodococcus equi (RHOE1)Protein coding sequence | Resistance to diseases and pests (Bacteria)
-
BCH-GENE-SCBD-107873-1 CoA-transferase beta subunit gene | Rhodococcus equi (RHOE1)Protein coding sequence | Resistance to diseases and pests (Bacteria)
-
BCH-GENE-SCBD-107876-1 CoA-transferase alpha 2 subunit gene | Rhodococcus equi (RHOE1)Protein coding sequence | Resistance to diseases and pests (Bacteria)
-
BCH-GENE-SCBD-107875-2 CoA-transferase beta 2 subunit gene | Rhodococcus equi (RHOE1)Protein coding sequence | Resistance to diseases and pests (Bacteria)
LMO R. equi RG2837 differs from its wild-type strain R. equi RE1 by the absence of most of the coding sequences of chromosomal genes ipdA, ipdB, ipdA2 and ipdB2 – genes which are involved in the cholesterol catabolism. Due to genetic engineering two recognition sites for restriction enzymes of 6 bp in length from the vectors pSelAct-ipd1 and pSelAct-ΔipdAB2 remained in the bacterial chromosome of RG2837.
EN
EN
- Vaccine
EN
EN
- The steroid catabolic pathway of the intracellular pathogen Rhodococcus equi is important for pathogenesis and a target for vaccine development [ English ]
- A novel method to generate unmarked gene deletions in the intracellular pathogen Rhodococcus equi using 5-fluorocytosine conditional lethality [ English ]
- Rhodococcus equi infection in foals: the science of ‘rattles’ [ English ]
Record type | Field | Record(s) | |||||
---|---|---|---|---|---|---|---|
|
|||||||
|